Lasmi

Lasmiditan is indicated for the acute treatment of migraine 

Serotonin 5-HT1F Receptor Agonist

Lasmiditan has high affinity to 5-HT1F receptor, but the full mechanism of action is unknown. It may decrease stimulation of the trigeminal system within meninges. 5-HT1B receptors in blood vessels are not activated, so vasoconstriction does not occur.

Usual dose: 50mg, 100mg, or 200mg single dose as needed for migraine. Max 1 dose per 24 hours Geriatric dose: initiate at low end of dosing range. Hepatic impairment dose: mild (Child-Pugh A) or moderate (Child-Pugh B): no dosage change needed severe (Child-Pugh C): Use not recommended

CNS Depressants:

Concomitant administration of Lasmiditan and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of Lasmiditan to cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions, Lasmiditan should be used with caution if used in combination with alcohol or other CNS depressants

Serotonergic Drugs:

Concomitant administration of Lasmiditan and drugs (e.g., SSRIs, SNRIs, TCAs, MAO inhibitors, trazodone, etc.), over-the counter medications (e.g., dextromethorphan), or herbal supplements (e.g., St. John’s Wort) that increase serotonin may increase the risk of serotonin syndrome. Use Lasmiditan with caution in patients taking medications that increase serotonin.

Heart Rate Lowering Drugs:

Lasmiditan has been associated with a lowering of heart rate. In a drug interaction study, addition of a single 200 mg dose of Lasmiditan to propranolol decreased heart rate by an additional 5 beats per minute compared to propranolol alone, for a mean maximum of 19 beats per minute. Use Lasmiditan with caution in patients taking concomitant medications that lower heart rate if this magnitude of heart rate decrease may pose a concern.

P-gp and Breast Cancer Resistant Protein (BCRP):

Lasmiditan inhibits P-gp and BCRP in vitro. Concomitant use of Lasmiditan and drugs that are P-gp or BCRP substrates should be avoided.

Precautions & Warnings Driving Impairment: Advise patients not to drive or operate machinery until at least 8 hours after taking each dose of Lasmi. Patients who cannot follow this advice should not take Lasmi. Patients may not be able to assess their own driving competence and the degree of impairment caused by Lasmi. Central Nervous System (CNS) Depression: Lasmi may cause CNS depression and should be used with caution if used in combination with alcohol or other CNS depressants. Serotonin Syndrome: Reactions consistent with serotonin syndrome were reported in patients treated with Lasmi. Discontinue Lasmi if symptoms of serotonin syndrome occur. Medication Overuse Headache: Detoxification may be necessary.

Dizziness • Sleepiness • Numbness • Feeling tired • Tingling

There are no data on the presence of lasmiditan in human milk, the effects of lasmiditan on the breastfed infant, or the effects of lasmiditan on milk production. Excretion of lasmiditan and/or metabolites into milk, at levels approximately 3 times those in maternal plasma, was observed in lactating rats following oral administration of lasmiditan. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Lasmiditan and any potential adverse effects on the breastfed infant from Lasmiditan or from the underlying maternal condition.

Store at 20°C to 25°C

As per physician